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Evidence on adverse effects of maternal macrolide use during pregnancy is inconsistent.
We conducted a systematic review and meta-analysis to investigate the association
between macrolide use during pregnancy and adverse fetal and child outcomes.
Methods and findings
We included observational studies and randomised controlled trials (RCTs) that recorded
macrolide use during pregnancy and child outcomes. We prioritized comparisons of macro-
lides with alternative antibiotics (mainly penicillins or cephalosporins) for comparability of
indication and effect. Random effects meta-analysis was used to derive pooled odds ratios
(OR) for each outcome. Subgroup analyses were performed according to specific types
(generic forms) of macrolide.
Of 11,186 citations identified, 19 (10 observational, 9 RCTs) studies were included (21
articles including 228,556 participants). Macrolide prescribing during pregnancy was associ-
ated with an increased risk of miscarriage (pooled ORobs 1�82, 95% CI 1�57–2�11, three
studies, I2 = 0%), cerebral palsy and/or epilepsy (ORobs 1�78, 1�18–2�69; one study), epi-
lepsy alone (ORobs 2�02, 1�30–3�14, one study; ORRCT 1.03, 0.79–1.35, two studies), and
gastrointestinal malformations (ORobs 1�56, 1�05–2�32, two studies) compared with alterna-
tive antibiotics. We found no evidence of an adverse effect on 12 other malformations, still-
birth, or neonatal death. Results were robust to excluding studies with high risk of bias.
Conclusions
Consistent evidence of an increased risk of miscarriage in observational studies and uncer-
tain risks of cerebral palsy and epilepsy warrant cautious use of macrolide in pregnancy with
warnings in drug safety leaflets and use of alternative antibiotics where appropriate. As
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Introduction
Macrolide antibiotics are one of the most commonly used class of antibiotics worldwide. [1,
2]. Major members of the class include erythromycin, azithromycin and clarithromycin. Over
the last 20 years, concerns have been raised about rare but serious adverse outcomes associated
with macrolide use during pregnancy [3–6]. The strongest evidence comes from a large rando-
mised controlled trial (RCT, ORACLE Child Study II) of women with spontaneous preterm
labour (SPL), which reported an increased risk of cerebral palsy in children whose mothers
received erythromycin (3�3%) compared with no erythromycin (1�7%, Odds Ratio (OR) 1�93,
95% Confidence Interval (CI): 1�21–3�09) [6]. Increased risks of miscarriage, major malforma-
tions, and cardiovascular malformation have also been reported in some observational studies
[3, 7–10], but not in others [11–13]. Currently there is no overview of the effects of macrolide
treatment during pregnancy in fetuses or children and no consensus about whether macrolides
are considered safe in pregnancy or not. In April 2015, the UK Medicines and Healthcare
products Regulatory Agency (MHRA) reviewed evidence indicating potential harmful effects
of macrolides on cerebral palsy or epilepsy reported by Meeraus et al [5], and decided there
was insufficient evidence to warn against macrolides use in pregnancy [14]. However, in Swe-
den, 2005, national policy advised against the use of erythromycin during early pregnancy [9].
Warnings have been also issued against use of azithromycin and clarithromycin in adults with
high risk of cardiovascular complications in the United States (US) [15, 16], based on evidence
of an unexpected increase in the risk of death and cardiovascular events including arrhythmias
and cardiac mortality (Azithromycin: 2 systematic reviews including 20 RCTs [17, 18]; clari-
thromycin: 1 RCT [19]).
Interpretation of existing research is challenging. In observational studies, the harm
observed after macrolides antibiotics exposure could be a consequence of infection–rather
than the use of macrolides (i.e. indication bias). On the other hand, RCTs are usually not
design to look at adverse event. In RCTs that compare macrolides with placebo, a “real” harm-
ful effect of macrolides could be masked due to its benefits of treating infection and thus only a
null or protective effect can be observed.
We conducted a systematic review and meta-analysis to determine the effects of macrolide
treatment during pregnancy on fetal and child outcomes. We prioritized comparisons between
macrolides and alternative antibiotics (mainly penicillins or cephalosporins) for assumed com-
parability of indication and treatment effects. RCTs where one of the arms included placebo or
drug combinations (e.g. erythromycin plus co-amoxiclav) are susceptible to incomparable
treatment effects and were therefore regarded as secondary comparisons. Based on previous
evidence from experimental and epidemiological studies, we hypothesized that short-term
fetal hypoxia induced by fetal arrhythmia could possibly be the underlying mechanism of
observed adverse effects of macrolides (S1 Text). We therefore included outcomes which could
potentially result from short-term fetal hypoxia (i.e. fetal and neonatal death, congenital mal-
formations, and conditions resulting from central nervous system damage). We presented
pooled effects of macrolides use in pregnancy on each outcome and explored heterogeneity of
the effect according to specific types of macrolides.
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Methods
A complete PRISMA harm checklist for this review is available in S1 Table. A protocol for this
review has not been previously published.
Eligibility criteria
Study types. We sought comparative studies which examined macrolide treatment during
pregnancy and adverse fetal and/or childhood outcomes that have been reported to be associ-
ated with fetal hypoxia. We included randomised controlled trials and observational (cohort
or case-control) studies and set different eligibility criteria for the comparator group according
to study type in order to address the risk of bias as explained below.
Participants, interventions and comparisons. The exposed populations were the fetuses
or children whose mothers were prescribed macrolide antibiotics during pregnancy. We
included studies that included all pregnancies or those that reported outcomes only in live-
births.
The primary analysis included studies comparing macrolide antibiotics with alternative
antibiotics e.g. penicillin or cephalosporin. Macrolides are recommended as the alternative for
women with suspected allergy to penicillin or cephalosporin, thereby minimising the risk of
indication bias due to infection [20, 21]. Penicillin and cephalosporin are also comparable
with macrolides in treatment effect with long-established safety records during pregnancy
[21]. This head to head comparison thus also allows the separation of possible harm of macro-
lides from their benefits of treatment on infection.
The secondary analysis includes RCTs with the following two comparisons: macrolide ver-
sus placebo and macrolides plus alternative antibiotics versus the same alternatives. Though
RCTs avoid indication bias by design, true adverse effects of macrolides may be masked by the
benefits of macrolides in reducing infection, thereby underestimating adverse effects.
Outcomes. We reviewed cohort studies of pregnant women and their children and exper-
imental studies in animals to identify outcomes that could potentially result from short term
fetal hypoxia, including fetal and neonatal death, congenital malformations, and conditions
resulting from central nervous system damage (i.e. epilepsy, cerebral palsy, ADHD and
autism) [21–23]. We excluded outcomes commonly related to chronic hypoxia (e.g. low birth-
weight, intrauterine growth restriction) or outcomes that might result from postnatal events
(e.g. abnormal cerebral ultrasonography).
Search strategy
Systematic literature searches were conducted in PubMed, Embase, Cochrane Library, Confer-
ence Proceeding Citation Index-Science and ClinicalTrials.gov from their respective inception
until Februry 15, 2018 (S2 Table). We included conference abstracts if sufficient data were pro-
vided. Further relevant studies were retrieved by hand searching the reference lists of eligible
papers and by using ‘Similar articles’ function within databases. No language restrictions were
applied.
Study selection
After removal of duplicates, the titles and abstracts of all identified records (full-text articles
and abstracts) were evaluated by reviewer HF, using a “decision tree” (S3 Table). Ten percent
of the records were also reviewed by another reviewer LW, and an inter-rater agreement was
calculated. A total of 967 studies were double reviewed with an inter-rater agreement of 81%.
All studies potentially meeting the inclusion criteria were reviewed in full by reviewer HF, and
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10% of the potentially eligible studies were reviewed by a third reviewer (LL). We resolved any
discrepancies through discussion. Reviewers were not blinded to authors, journals or
institutions.
Data extraction
We developed and piloted a data extraction sheet on 15 relevant studies. Reviewer HF
extracted relevant data from included studies. We contacted authors of potentially eligible
manuscripts by email for relevant data if this could not be extracted from the publication.
Where the same cohort was reported more than once, we extracted data from the study with
the largest sample size.
For studies reporting multiple comparisons of each specific type of macrolides (vs same
comparator), we divided the comparator group equally for each comparison. For studies pre-
senting multiple estimates of exposure on both whole pregnancy and the first trimester, the
estimate of exposure on the first trimester was included in the meta-analysis to avoid a poten-
tial dilution effect.
Risk of bias assessment
We used risk of bias assessment tools for RCTs (Cochrane Collaboration’s tool for assessing
risk of bias in randomised trials) and observational studies (Risk of Bias In Non-Randomised
Studies–of Interventions (ROBIN-I)). The tool for RCTs was modified by including sections
on masked adverse effect (susceptible when one of the arms was placebo or drug combina-
tions, as mentioned in the eligibility criteria). We considered observational comparisons of
macrolides versus alternative antibiotics to be at low or moderate risk of indication bias, pro-
vided there is no evidence of macrolides indication apart from that of alternative antibiotics
(S4 and S5 Tables) [24, 25].
Data synthesis and analysis
We estimated the pooled ORs for each adverse outcome using a random-effects meta-analysis,
considering the heterogeneity among studies which was measured by I2 statistics. RCTs and
observational studies were analysed separately. In the primary analysis, we compared macro-
lides with alternative antibiotics in RCTs and observational studies. In the secondary analyses,
we included RCTs which compared (1) macrolides with alternative antibiotics, (2) macrolides
with placebo and (3) macrolides plus alternative antibiotics with the same alternatives. We
summarized the results according to specific types of macrolide in subgroup analysis. Sensitiv-
ity analysis was performed according to risks of bias.
Studies with no observed events were excluded from the meta-analysis. For studies with no
events in one of the two groups, we applied a correction proportional to the reciprocal of the
size of the contrasting study arm [26]. For observational studies, we used the adjusted OR if
reported, otherwise, we re-calculated the crude OR using the data reported. Funnel plot asym-
metry was not assessed because of an insufficient number of studies. Analyses were performed
using R 3�4�1 (R Foundation for Statistical Computing, Vienna, Austria).
Role of funding source
The funders of this study had no role in study design, data collection, analysis and interpreta-
tion, or writing of the report. The corresponding author had full access to all the data in the
study and had final responsibility for the decision to submit for publication.
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Results
Of the 11,186 citations identified, we selected 99 abstracts for detailed assessment (Fig 1). 14
articles based on 12 studies (2 RCTs and 10 observational studies, 190,368 pregnancies or live
births) met our inclusion criteria for primary analysis. Secondary analysis included 9 RCTs
published in 11 articles of 15,405 pregnancies. Characteristics of the included studies are listed
in S6 Table [3–8, 10, 13, 27–39].
Fig 1. Study selection.
https://doi.org/10.1371/journal.pone.0212212.g001
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Overall, 12/14 (85�7%) articles in the primary analysis were judged to have low or medium
overall risk of bias (Fig 2). Adjusted ORs were available for four of ten observational studies [5,
7, 8, 10].
All three observational studies in the primary analysis reporting the risk of miscarriage in
the primary analysis showed an increased odd of miscarriage for mothers prescribed macrolide
antibiotics compared with those prescribed alternative antibiotics, with a pooled OR of 1�82
(95% CI 1�57–2�11) (Fig 3 and S2 Fig) [3, 7, 8]. No RCTs included evaluated the risk of miscar-
riage. Given the lowest risk ratio estimate in one of the three studies as 1�51, the number
needed to harm (NNH) for miscarriage ranges from 10 at 6 weeks’ gestation to 196 at 20
weeks, with the baseline risks of 20% and 1%, respectively [7, 40]. Compared with alternative
antibiotics, odds of miscarriage increased significantly in subgroups prescribed azithromycin
and clarithromycin, but not in the subgroup prescribed erythromycin (S3 Fig).
Two RCTs (4 articles) and 2 observational studies reported the association between macro-
lides use in pregnancy and stillbirth, neonatal death or “stillbirth and neonatal mortality” [3, 6,
13, 29–31]. The odds of these outcomes did not differ between macrolides and alternative anti-
biotics prescription. (Fig 3, S2 and S4 Figs).
No increase was noted in risks for cerebral palsy or epilepsy in 2 RCTs, one of women with
SPL and the other of women with preterm, prelabour rupture of fetal membranes (pPROM)
[6, 29]. However, in one large cohort study of Meeraus et al, the odds for epilepsy and a
Fig 2. Assessment of bias. a: Evaluated as moderate risk in secondary analysis (low risk in primary analysis) due to incomparable treatment effect. b: Studies
only eligible for secondary analysis. c: In the study of Andersen (2013), the OR was adjusted by maternal age, number of previous miscarriages, income and
education. d: In the study of Le guyen, the OR was adjusted by maternal age, long-term illnesses, parity and multiple pregnancy. e: In the study of Meeraus
(2015), the Hazard Ratio was adjusted by maternal age, Townsend quintile, year of delivery, smoking, alcohol problems, obesity, illicit drug use, treatment of
chronic medical conditions and potentially neurologically-damaging infection during pregnancy. f: In the study of Muanda (2017), cases and controls were
matched by gestational age and year of pregnancy; in the analysis of specific macrolides, the ORs were adjusted by 11 covariates, e.g. maternal age, education
level, chronic comorbidities, maternal infections (urinary tract infection, respiratory tract infection, bacterial vaginosis and sexually transmitted infections) and
prior exposure to antibiotics.
https://doi.org/10.1371/journal.pone.0212212.g002
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PLOS ONE | https://doi.org/10.1371/journal.pone.0212212 February 19, 2019 6 / 14
composite outcome “cerebral palsy and/or epilepsy” increased significantly in unselected
mothers prescribed to macrolides compared with penicillins, with an NNH of 245 and 214,
given the baseline risks of 0.4% and 0.6%, respectively (Fig 3, S2 and S4 Figs) [5, 41].
Seven observational studies evaluated the risk of malformations. No difference in risk was
identified for “all malformations”, major malformations, cardiovascular malformations and
pyloric stenosis. The results of other organ-specific malformations were dominated by one
study of Muanda et al [36]. A significant but weak increase in the risk of gastrointestinal con-
genital malformations was observed in mothers prescribed macrolide antibiotics (with the
NNH of 744, given a baseline incidence of 2�4 per 1000 live births) [42]. Evidence for specific
types of macrolides was limited. Azithromycin was significantly associated with major, gastro-
intestinal and muscular-skeletal malformations. Erythromycin was the only macrolide signifi-
cantly associated with orofacial malformations and cleft palate or cleft lip (Fig 3, S2 and S3
Figs).
Secondary analyses of RCTs with one arm as drug combinations or placebo showed similar
results to those from the primary analysis [28, 32–35, 37, 38]. (S5 Fig). In the sensitivity analy-
sis, restriction of analyses to comparisons with low or moderate risk of bias (applicable to mis-
carriage, “all malformation” and major malformation) did not alter the conclusions of primary
analysis (S7 Fig).
Fig 3. Primary and secondary analysis for the association between prenatal use of macrolides and adverse child outcomes.
https://doi.org/10.1371/journal.pone.0212212.g003
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Discussion
We report a systematic review and meta-analysis of associations between maternal macrolide
antibiotics exposure and adverse child outcomes. Macrolide antibiotics use during pregnancy
(vs alternative antibiotics) was associated with an increased risk of miscarriage, but evidence
for its association with cerebral palsy and epilepsy were inconsistent. We found only weak evi-
dence for an association with gastrointestinal malformations and insufficient evidence with
other malformations, stillbirth or neonatal death.
To our knowledge, this review is the first systematic assessment of the adverse fetal and
child outcomes of macrolides use during pregnancy. The increased risk of miscarriage and
inconsistent evidence for cerebral palsy and epilepsy suggests that macrolides may have the
potential to cause adverse effects when used in pregnancy. Evidence from experimental and
epidemiological studies in adults also indicates biological plausibility of embryotoxicity and
cardiotoxity of exposure to azithromycin and clarithromycin (S1 Text). As the aetiology of
these fetal adverse outcomes is multifactorial, the increase of absolute risk can be small for
some conditions. Dependencies between comparisons may exist when we split the comparator
groups and evaluated more than one outcomes from one study. Very few studies were available
for each outcome, which resulted in imprecision in the heterogeneity estimates.
To address potential bias due to treatment indication, in the primary analysis we included
only head-to-head comparisons, most of which (42 out of 47 comparisons, 89%) were between
macrolides and penicillins. Macrolides are often used as replacement therapy for patients with
penicillin allergy [20]. There are unique indications of macrolides (e.g. azithromycin for
gonorrhoea, chlamydia and mycoplasma infection) which could be linked to increased risk of
miscarriage [43]. However, the indications of clarithromycin do not include genitourinary
tract infections according to guidelines in both Europe and North America [44–47]. Yet all
three studies in this review reported consistent increased risks of miscarriage associated with
clarithromycin [3, 7, 8]. Furthermore, it is estimated that over 20% penicillins prescribed at
pregnancy are for genitourinary tract infection [1]. Therefore the increased risk of miscarriage
observed in this review is unlikely to be over-estimated due to indications of macrolides.
Among the three studies on miscarriage, two are large studies using Canadian and Danish reg-
istries. The Canadian study was a good-quality nested case-control study matched by gesta-
tional age, with adjustment for types of maternal infections (including sexually transmitted
infections) and proxies for infection severity [8]. Indication was also analysed in the Danish
study by comparing clarithromycin with erythromycin, phenoxymethylpenicillin, amoxicillin
and proton pump inhibitors adjusted by maternal characteristics, with consistent evidence of
increased risks of miscarriage in the clarithromycin group (S6 Table) [7].
Another source of bias in studies on outcomes that manifest after birth (e.g. cerebral palsy,
epilepsy and malformations) is survivor bias. Assuming an increased risk of fetal death (i.e.
miscarriage) in fetuses exposed to macrolides (vs penicillin), both fetuses exposed to macro-
lides and fetuses with adverse outcome were less likely to be selected in studies conditioning
on live-birth status. Thereby this survivor bias would weaken the association between macro-
lides and adverse outcomes in live-born children. The observed risk ratios for gastrointestinal
malformation, cerebral palsy and epilepsy in this review may therefore be underestimated due
to survivor bias. The potential effects of survivor bias is illustrated by a post-hoc simulation in
S2 Text.
Heterogeneity exists among studies due to study design (RCT or observational), population
of pregnant women studied, specific types of macrolides, and gestational ages for administer-
ing macrolides. Our analyses of RCTs were dominated by studies of mothers at high risk of
fetal infection, e.g. mothers with pPROM or urinary tract infections. Comparing with placebo,
Prenatal use of macrolide antibiotics and adverse child outcomes
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these mothers stand to benefit from the treatment effect of macrolides, masking evidence of its
potential harm. However, in mothers with SPL, who bore a relatively low risk of fetal infection,
masked harm from macrolides due to its treatment benefits is reduced. Reduced risk of fetal
infection may explain the finding of significantly increased risk of cerebral palsy in mothers
with SPL, but not in mothers with pPROM in secondary analysis (S5 Fig).
Evidence of heterogeneity in adverse outcomes according to specific types of macrolides is
limited because of few studies. The increased risk of miscarriage was found predominantly
among those used azithromycin and clarithromycin in pregnancy, but not those used erythro-
mycin (1895 in total). Reasons for this difference are not clear. Fewer gastrointestinal side-
effects and better pharmacokinetic profiles (e.g. better oral bioavailability, tissue penetration
and longer half-life of elimination) of clarithromycin and azithromycin may increase their
maternal and fetal bioavailability compared with erythromycin [48]. Meanwhile, an ex vivo
experiment with term human placentas found that the transplacental transfer is higher for
clarithromycin while similar between azithromycin and erythromycin (percentage transfer at
2.6%, 3% and 6%, respectively) [49].
Timing of treatment according to critical periods of gestation also contributes to heteroge-
neous effects. Fetuses are most vulnerable to teratogenic effects during certain time windows
(e.g., day 28–56 of gestation is the critical period for heart formation) [50, 51]. Romoren et al.
found when the window of macrolides exposure was reduced from the first trimester to 28–56
days of gestation, the adjusted OR of cardiovascular malformation increased from 0�96 to 1�36,
although they were nonsignificant due to limited power [13]. This increased OR was similar to
those reported by Kallen et al in 2005 and 2014[4, 9], which was also consistent with the effect
of IKr-blockers observed in animal studies and epidemiological studies [50, 52, 53]. These find-
ings highlight the possibility of underestimating the adverse effect of macrolides, by measuring
the macrolides exposure outside of critical period for fetal development [2, 27, 36, 54].
Clinical relevance
According to British National Formula, comment given to erythromycin usage during preg-
nancy states “Not known to be harmful” [20]. The National Institute for Health and Care
Excellence (NICE) guidance recommends erythromycin and clarithromycin as replacements
for penicillin allergy for upper respiratory infection (in pregnant women) [55]. The UK Tera-
tology Information Advisory Service recommend that “as the number of documented expo-
sures during pregnancy is limited, azithromycin should be avoided during pregnancy unless
alternatives such as erythromycin are inappropriate” and “It would be reasonable, where alter-
native antimicrobials are available, to avoid clarithromycin in the first trimester of pregnancy”
[56–58]. In view of the consistent evidence for an increased risk of miscarriage in mothers pre-
scribed macrolides, with a number needed to harm of 10 in first 6 weeks to 196 at 20 weeks of
gestation, guidelines should be updated to avoid macrolides during the first half of pregnancy.
The uncertain increased risks of cerebral palsy and epilepsy following macrolide treatment at
any point during pregnancy should be reported in drug safety leaflets and alternative antibiot-
ics recommended where appropriate.
Conclusions
Evidence is consistent with an increased risk of miscarriage in mothers prescribed macrolides
during pregnancy compared with alternative antibiotics. The risk of cerebral palsy and epi-
lepsy is uncertain, and there is weak or no evidence for adverse effects on congenital malfor-
mations. These findings warrant caution about the use of macrolides in pregnancy and use of
alternatives where appropriate. As macrolides are the third most commonly used class of
Prenatal use of macrolide antibiotics and adverse child outcomes
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antibiotics, it is important to confirm these results with larger, high quality studies to investi-
gate associations between specific types of macrolides and rare events, such as cerebral palsy,
epilepsy and organ-specific malformations.
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